GH Research/$GHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Ticker
$GHRS
Sector
Primary listing
Employees
50
Headquarters
Dublin, Ireland
Website
GH Research Metrics
BasicAdvanced
$834M
-
-$0.79
0.97
-
Price and volume
Market cap
$834M
Beta
0.97
52-week high
$20.50
52-week low
$6.00
Average daily volume
311K
Financial strength
Current ratio
29.71
Quick ratio
29.376
Long term debt to equity
0.104
Total debt to equity
0.212
Interest coverage (TTM)
-94.01%
Profitability
EBITDA (TTM)
-51.455
Management effectiveness
Return on assets (TTM)
-11.97%
Return on equity (TTM)
-16.20%
Valuation
Price to book
2.69
Price to tangible book (TTM)
2.69
Price to free cash flow (TTM)
-17.418
Free cash flow yield (TTM)
-5.74%
Free cash flow per share (TTM)
-0.772
Growth
Earnings per share change (TTM)
26.64%
3-year earnings per share growth (CAGR)
40.67%
What the Analysts think about GH Research
Analyst ratings (Buy, Hold, Sell) for GH Research stock.
Bulls say / Bears say
GH Research's Phase 2b trial of GH001 in treatment-resistant depression met its primary endpoint, demonstrating a significant placebo-adjusted MADRS reduction of -15.5 points on Day 8, with a 57.5% remission rate compared to 0% in the placebo group, indicating strong efficacy. (GH Research News Release)
The company successfully completed a $150 million public offering at $15.00 per share, strengthening its financial position to support ongoing clinical development and potential commercialization efforts. (GH Research News Release)
Analysts have shown confidence in GH Research, with Cantor Fitzgerald initiating coverage with an 'overweight' rating and a $25.00 price target, suggesting a potential upside of 98.26% from the stock's previous close. (American Market News)
The recent $150 million public offering, while bolstering the company's cash reserves, resulted in approximately 18.3% dilution to existing shareholders, which may impact earnings per share in the near term. (Stock Titan)
Despite positive trial results, GH Research remains a clinical-stage company with no approved products, and the path to regulatory approval and commercialization carries inherent risks and uncertainties. (GH Research News Release)
The company's financial reports indicate increased research and development expenses, leading to a net loss of $12.1 million in Q3 2024, highlighting ongoing operational challenges. (GH Research News Release)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
GH Research Financial Performance
Revenues and expenses
GH Research Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $834M as of August 05, 2025.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of August 05, 2025.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of August 05, 2025.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.